70804-88-5

Upstream product

• 24639-06-3 ((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 32976-08-2 (2R,3R,4S,5R)-2-(6-amino-2-methylsulfanyl-9H-purin-9-yl)tetrahydrofuran-3,4-(O-isopropylidene) 
• 436847-42-6 Phosphoric acid (3aR,4R,6R,6aR)-6-(6-amino-2-methylsulfanyl-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester di-tert-butyl ester 
• 4105-39-9 2-(methylthio)adenosine 

Relevant academic research and scientific papers

NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS

The invention features compounds of formula I and methods of their use as antiplatelet and antithrombotic compounds: H /N=Qχ2 O O O O Λ Q2 — N, H R6/ N I f ) ( ^ XM O-Mγτ OM°τ X1MQ' ) r ( ^rf HO OH HO OQHi Nχi R2 Formula (I).

Identification of hydrolytically stable and selective P2Y1 receptor agonists

P2Y nucleotide receptors (P2YRs) are attractive pharmaceutical targets. Most P2YR agonists proposed as drugs consist of a nucleotide scaffold, but their use is limited due to their chemical and enzymatic instabilities. To identify drug candidates, we deve

Adenine nucleotide analogues locked in a Northern methanocarba conformation: Enhanced stability and potency as P2Y1 receptor agonists

Preference for the Northern (N) ring conformation of the ribose moiety of nucleotide 5′-triphosphate agonists at P2Y1, P2Y2, P2Y4, and P2Y11 receptors, but not P2Y6 receptors, was established using a

The preparation of 32P-labeled 2-methylthioadenosine di- and triphosphates

2-Methylthioadenosine 5′-mono- and diphosphates were prepared by chemical synthesis, and enzymatically phosphorylated to 5′-[β-32P]-diphosphate and 5′-[γ-32P]-triphosphate, respectively. They were isolated by HPLC and had activity exceeding 1000 Ci/mmol and radiochemical purity higher than 95%.